Technical Questions

Before I start, I just want to say that I have faith in the company's ability to generate revenue from its current icence agreement with P&G, GSK etc and grabbed another parcel at $0.105 yesterday.

However, I brought up OBJ recently with a friend and he consulted with his biotech analyst and some of the feedback include:-

1. It does not have a very good product,and
2. The company seems to change and restructure to sell something different

My question to the more informed poster is that, are these comments valid? Personally, my view is that it does not matter if previous products fail/underperform, you only need to have one product that works.

Thanks in advance!